抗肥満薬市場：薬剤タイプ、作用機序別-2025-2030年の世界予測

抗肥満薬市場は、2023年に38億3,000万米ドルと評価され、2024年には40億9,000万米ドルに達すると予測され、CAGR 6.86％で成長し、2030年には61億米ドルに達すると予測されています。

抗肥満薬市場の範囲には、食欲減退、満腹感増大、栄養吸収阻害によって体重減少を促進するように設計された医薬品が含まれます。世界の肥満率の急上昇に伴い、効果的な薬理学的介入の必要性は、体重管理だけでなく、糖尿病、心血管疾患、特定のがんなどの関連する健康リスクを軽減するためにも極めて重要になっています。最終用途はヘルスケアプロバイダーや病院から小売薬局や研究機関まで多岐にわたる。

この市場の主な成長要因は、肥満に関連する健康リスクに対する意識の高まり、医薬品開発の技術的発展、肥満管理を提唱する政府の支援政策です。世界の座りがちなライフスタイルや不健康な食事パターンの増加は、効果的な肥満対策ソリューションの必要性をさらに高めています。この分野の潜在的なビジネスチャンスとしては、遺伝子プロファイルに基づいて治療を調整する個別化医療のアプローチや、薬効を高めるための併用療法の探求などが挙げられます。企業は、研究開発に投資して副作用の少ないより強力な薬剤を開発し、特に肥満率が上昇している新興経済諸国において地理的範囲を拡大することで、市場での地位を強化することができます。

市場開拓を阻む課題としては、規制当局の厳しい承認、薬剤開発コストの高さ、薬剤の潜在的副作用、肥満治療に対する社会的烙印などが挙げられます。さらに、ライフスタイルや外科的治療が好まれるため、薬理学的介入に懐疑的な世論によって市場浸透が制限されています。イノベーションは、インスリン増感剤、腸内細菌叢を標的とする薬剤、患者のアドヒアランスと転帰を改善するために薬剤レジメンと統合するデジタルヘルス技術の機会の開発に焦点を当てるべきです。持続的な成長のためには、包括的な治療計画の重要性を強調し、薬剤の有効性に関する実際のエビデンスを強調し、薬剤の安全性と有効性に関する一般大衆の誤解に対処するために、企業は医療提供者との協力を促進すべきです。市場の競争は依然として激しく、企業は戦略的パートナーシップと患者中心のイノベーションを通じて継続的に進化する必要があります。

市場力学：急速に進化する抗肥満薬市場の主要市場インサイトを公開

抗肥満薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 肥満と関連慢性疾患の負担増
  • 不健康なファーストフードや惣菜の消費急増
  • 健康志向の高まり
• 市場抑制要因
  • 医薬品に伴う副作用
• 市場機会
  • 共同戦略を持つ人々の意識の高まり
  • 最近の肥満治療薬の進歩
• 市場の課題
  • 市場における代替治療オプションの利用可能性

ポーターのファイブフォース：抗肥満薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗肥満薬市場における外部からの影響の把握

外部マクロ環境要因は、抗肥満薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析抗肥満薬市場における競合情勢の把握

抗肥満薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス抗肥満薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗肥満薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨抗肥満薬市場における成功への道筋を描く

抗肥満薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肥満とそれに関連する慢性疾患の負担増大
    • 不健康なファーストフードや出来合いの食事の急速な消費
    • 健康とフィットネスへの関心の高まり
  • 抑制要因
    • 薬に伴う副作用
  • 機会
    • 協働戦略に対する人々の意識の高まり
    • 肥満の薬物治療における最近の進歩
  • 課題
    • 市場における代替治療オプションの可用性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 抗肥満薬市場薬の種類別

• 市販薬
• 処方薬

第7章 抗肥満薬市場作用機序別

• 中枢作用薬
• 末梢作用薬

第8章 南北アメリカの抗肥満薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の抗肥満薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの抗肥満薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Currax Pharmaceuticals LLC
• Eisai Co. Ltd
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Norgine BV
• Novo Nordisk AS
• Pfizer Inc.
• Rhythm Pharmaceuticals, Inc.
• SHIONOGI & Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Vivus Inc.

LIST OF FIGURES

• FIGURE 1. ANTI-OBESITY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ANTI-OBESITY DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTI-OBESITY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTI-OBESITY DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CENTRALLY ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 20. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 21. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 32. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 33. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 34. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 69. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 77. POLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. POLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 79. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 99. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 100. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Anti-Obesity Drugs Market was valued at USD 3.83 billion in 2023, expected to reach USD 4.09 billion in 2024, and is projected to grow at a CAGR of 6.86%, to USD 6.10 billion by 2030.

The scope of the anti-obesity drugs market encompasses pharmaceuticals designed to facilitate weight loss by reducing appetite, increasing satiety, or inhibiting nutrient absorption. With global obesity rates soaring, the necessity for effective pharmacological interventions has become critical, not only to manage weight but also to mitigate associated health risks like diabetes, cardiovascular diseases, and certain cancers. The primary applications include chronic weight management for patients with a significant body mass index (BMI), and the end-use scope ranges from healthcare providers and hospitals to retail pharmacies and research institutions.

Key growth factors in this market are driven by the increasing awareness of health risks linked to obesity, technological advancements in drug development, and supportive governmental policies advocating for obesity management. The rise in sedentary lifestyles and unhealthy diet patterns worldwide further escalates the need for effective anti-obesity solutions. Potential opportunities in this sector include personalized medicine approaches that tailor treatments based on genetic profiles and the exploration of combination therapies to enhance drug efficacy. Companies can strengthen their market position by investing in R&D to develop more potent drugs with fewer side effects and by expanding their geographical reach, especially in emerging economies where obesity rates are climbing.

Challenges impeding market growth consist of stringent regulatory approvals, high costs of drug development, potential side effects of medications, and societal stigma linked to obesity treatments. Moreover, market penetration is limited by public skepticism towards pharmacological interventions due to the preference for lifestyle and surgical treatments. Innovations should focus on developing insulin sensitizers, gut microbiota-targeting drugs, and opportunities for digital health technologies that integrate with drug regimens to improve patient adherence and outcomes. For sustained growth, businesses should foster collaborations with healthcare providers to emphasize the importance of comprehensive treatment plans, highlight real-world evidence of drug effectiveness, and address public misconceptions about medication safety and efficacy. The market's nature remains highly competitive, requiring firms to continuously evolve through strategic partnerships and patient-centric innovations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Obesity Drugs Market

The Anti-Obesity Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising burden of obesity and related chronic diseases
  • Rapid consumption of unhealthy fast-foods and ready meals
  • Increasing inclination towards health & fitness
• Market Restraints
  • Side-effects associated with drugs
• Market Opportunities
  • Growing awareness among people with collaborative strategies
  • Recent advancements in drug treatment of obesity
• Market Challenges
  • Availability of alternative treatment options in market

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Obesity Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Obesity Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Obesity Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Obesity Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Obesity Drugs Market

A detailed market share analysis in the Anti-Obesity Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Obesity Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Obesity Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Obesity Drugs Market

A strategic analysis of the Anti-Obesity Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Drugs Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co. Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus Inc..

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Over-The-Counter Drugs and Prescription Drugs.
• Based on Mechanism of Action, market is studied across Centrally Acting Drugs and Peripherally Acting Drugs.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising burden of obesity and related chronic diseases
    • 5.1.1.2. Rapid consumption of unhealthy fast-foods and ready meals
    • 5.1.1.3. Increasing inclination towards health & fitness
  • 5.1.2. Restraints
    • 5.1.2.1. Side-effects associated with drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing awareness among people with collaborative strategies
    • 5.1.3.2. Recent advancements in drug treatment of obesity
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of alternative treatment options in market
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-Obesity Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Over-The-Counter Drugs
• 6.3. Prescription Drugs

7. Anti-Obesity Drugs Market, by Mechanism of Action

• 7.1. Introduction
• 7.2. Centrally Acting Drugs
• 7.3. Peripherally Acting Drugs

8. Americas Anti-Obesity Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Anti-Obesity Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Anti-Obesity Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bayer AG
• 2. Boehringer Ingelheim International GmbH
• 3. Bristol-Myers Squibb Company
• 4. Currax Pharmaceuticals LLC
• 5. Eisai Co. Ltd
• 6. F. Hoffmann-La Roche AG
• 7. GlaxoSmithKline PLC
• 8. Merck & Co. Inc.
• 9. Norgine BV
• 10. Novo Nordisk AS
• 11. Pfizer Inc.
• 12. Rhythm Pharmaceuticals, Inc.
• 13. SHIONOGI & Co., Ltd.
• 14. Takeda Pharmaceutical Company Limited
• 15. Vivus Inc.